Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Spruce Biosciences ( (SPRB) ) just unveiled an announcement.
On December 11, 2025, Spruce Biosciences, Inc. appointed Keli Walbert as a Class I Director, with her term expiring at the 2027 Annual Meeting of Stockholders. She was also appointed to the Compensation Committee and will receive stock options and a cash retainer as part of her compensation. This appointment is expected to enhance the company’s governance structure, with no related person transactions disclosed between Ms. Walbert and the company.
The most recent analyst rating on (SPRB) stock is a Buy with a $160.00 price target. To see the full list of analyst forecasts on Spruce Biosciences stock, see the SPRB Stock Forecast page.
Spark’s Take on SPRB Stock
According to Spark, TipRanks’ AI Analyst, SPRB is a Underperform.
Spruce Biosciences faces substantial financial challenges with declining revenues and persistent losses. Bearish technical indicators and unfavorable valuation metrics further weigh on the stock. The strategic acquisition of TA-ERT offers potential growth, but the financial instability remains a critical concern.
To see Spark’s full report on SPRB stock, click here.
More about Spruce Biosciences
Average Trading Volume: 568,997
Technical Sentiment Signal: Buy
Current Market Cap: $89.27M
For detailed information about SPRB stock, go to TipRanks’ Stock Analysis page.